LXEO — Lexeo Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $401.25m
- $208.93m
Annual cashflow statement for Lexeo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.6 | -59.3 | -66.4 | -98.3 | -100 |
| Depreciation | |||||
| Non-Cash Items | 0.387 | 2.66 | 4.84 | 13.8 | 10.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.04 | 1.79 | 1.48 | 2.73 | -9.52 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -44.2 | -54.6 | -59.5 | -81.2 | -98.6 |
| Capital Expenditures | -0.188 | -0.901 | -0.165 | -0.481 | -0.397 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | -93.6 | -89.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.188 | -0.901 | -0.165 | -94.1 | -90.3 |
| Financing Cash Flow Items | -0.372 | 0 | 100 | — | -16.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 151 | 0.189 | 104 | 88.8 | 217 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 106 | -55.3 | 44.1 | -86.5 | 28 |